Close

Melt Pharmaceuticals (MELT) Announces Proposed IPO

September 22, 2022 6:05 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Melt Pharmaceuticals (NASDAQ: MELT) has filed for a proposed IPO.

The analyst comments: "Melt is a clinical stage pharmaceutical company focused on the development and commercialization of proprietary non-opioid, non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient and in-office settings. We intend to seek regulatory approval through the FDA’s 505(b)(2) regulatory pathway for these proprietary, patented small-molecule product candidates, where possible. The core intellectual property we own is a patented series of combination non-opioid sedation drug formulations that we believe have multiple clinical applications for potential indications of use."

AEGIS CAPITAL CORP will serve as sole underwriter.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, IPOs

Related Entities

IPO, FDA